Day 2Wednesday, 19 June 2024 - ET (Eastern Time, GMT-05:00)

Navigate the implications of GFI #256 (2023) on veterinary medicine and animal drug compounding from the bulk drug substance list.

With the advent – and shortage – of blockbuster GLP-1s over the past 24 months, many Americans are learning about pharmacy compounding for the first time. But much of the media's reporting on shortage drug compounding is inaccurate and misleading. In this session, learn why FDA's shortage drug compounding policies are intentional and essential, what the media gets wrong about compounded GLP-1s in particular, and what compounding professionals should be telling their patients.

• Understanding the desired or required regulatory standard for your organization

• Building a stability program framework tailored around that regulatory standard

• Differences amongst types of organizations – Hospitals, 503A, or 503B

• Successful achievement of Beyond Use Dating or Expiration Dating

The FDA has reclassified multiple peptides to the category 2 bulks list due to recently identified safety risks. Join us as we discuss the anticipated implications of these reclassifications in the compounding space

• Gain insights on the challenges with compounded medications not covered by insurance/medicare
• Explore key strategies in liaising with FDA and state boards and state licensing

• Training and retaining pharmacists and technicians
• Finding qualified talent and following protocol to reduce medication errors
• Understanding certification reports